In patients with psoriasis, the utilization of biologic therapies contrasted and conventional systemic therapies (CST)/topical treatments is related with a comparative or lower hazard for creating adverse medicinal conditions, as indicated by study results published in the Journal of Drugs in Dermatology.
In this retrospective cohort study, information from a huge US administrative claims database were utilized to explore the real-world risk for development of adverse medical conditions in adult patients with psoriasis treated with CST/topical therapies versus patients treated with biologic agents. Members were arranged into cohorts dependent on the treatment started on the index date: adalimumab, etanercept, infliximab, ustekinumab, or CST/topical therapies. Occurrence adverse medical conditions recognized while on treatment from diagnoses recorded in medical claims included infections, malignancies (skin and nonskin), respiratory disease, mental disorders, and abnormal test results.
The following assessments were made: adverse medical condition risk with adalimumab, etanercept, and ustekinumab separately versus CST/topical therapies and adverse medical condition risk with adalimumab vs other biologic agents (etanercept, infliximab, and ustekinumab combined).
A total of 42,981 patients were identified (adalimumab: n=5197; etanercept: n=3311; infliximab: n=187; ustekinumab: n=1370; CST/topical therapies: n=32,916). Across the various cohorts, 46.2% to 53.1% of the members were women, median age was 46 to 50, and the median duration of follow-up was 3.3 to 7.9 months.
Infection was the most generally commonly reported adverse medical condition in all cohorts (28.7% to 41.8% of patients). Adalimumab, etanercept, and ustekinumab were all associated with an significantly lower chance for infection contrasted and CST/topical therapies (adjusted hazard ratio [aHR] 0.93, 0.92, and 0.86, respectively; P <.05 for all).
Moreover, treatment with adalimumab was related with an significantly lower hazard for malignancies (aHR 0.71; P <.05) and treatment with etanercept was related with a significantly lower risk for respiratory disease (aHR 0.80; P <.05). At the point when adalimumab was contrasted and other biologic agents,a similar safety profile was reported with respect to the adverse medical conditions that were evaluated.